Novo Nordisk's new CagriSema obesity drug trial to begin on Feb. 10, clinicaltrials.gov entry shows
Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, ...
STAT11h
RFK Jr.’s confirmation hearings, MASH drugs, and a controversial obesity ad
Why have drugs to treat the liver disease MASH reached a tipping point? How did Hims & Hers convince Childish Gambino to ...
STAT6d
Pharmalittle: We’re reading about scrubbing diversity from the FDA website, a Novo scolding, and more
The scrubbing of clinical trial-related pages is notable because of how it could affect the ways researchers both inside and ...
Healio1d
Increase in online searches for obesity drugs correlates with rise in prescriptions
The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...
EurekAlert!2d
Longitudinal analysis of obesity drug use and public awareness
This repeated cross-sectional study including 69.2 million obesity management drug dispensed prescriptions revealed an increase from 0.76 million in July 2017 to 1.5 million in February 2024, with an ...
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Healio6d
Novel obesity drug induces up to 22% weight loss with no safety concerns
A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...
BioSpace3d
Veru’s Drug Spares Lean Mass in Overweight, Obese Adults on Wegovy—Is It Enough?
Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...
Novo Nordisk Shares Surge on New Obesity Drug Results
Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...